U.S. Oncology Molecular Diagnostics Market (By Type: Breast Cancer, Liver Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, Other Cancer, By Technology; PCR, Sequencing, In Situ Hybridization, INAAT, Chips and Microarrays, Mass Spectrometry, TMA, Others; By Product, Reagents, Instruments, Others) - Regional Outlook and Forecast 2024 to 2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Oncology Molecular Diagnostics Market
5.1. COVID-19 Landscape: U.S. Oncology Molecular Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: U.S Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Oncology Molecular Diagnostics Market, By Type
8.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Type, 2024-2033
8.1.1 Breast Cancer
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Liver Cancer
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Prostate Cancer
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Colorectal Cancer
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Cervical Cancer
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
8.1.6. Lung Cancer
8.1.6.1. Market Revenue and Volume Forecast (2021-2033)
8.1.7. Blood Cancer
8.1.7.1. Market Revenue and Volume Forecast (2021-2033)
8.1.8. Kidney Cancer
8.1.8.1. Market Revenue and Volume Forecast (2021-2033)
8.1.9. Other Cancer
8.1.9.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. U.S. Oncology Molecular Diagnostics Market, By Technology
9.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Technology, 2024-2033
9.1.1. PCR
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Sequencing
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. In Situ Hybridization
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. INAAT
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Chips and Microarrays
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
9.1.6. Mass Spectrometry
9.1.56.1. Market Revenue and Volume Forecast (2021-2033)
9.1.7. TMA
9.1.7.1. Market Revenue and Volume Forecast (2021-2033)
9.1.8. Others
9.1.8.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. U.S. Oncology Molecular Diagnostics Market, By Product
10.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Product, 2024-2033
10.1.1. Reagents
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Instruments
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. U.S. Oncology Molecular Diagnostics Market, U.S Estimates and Trend Forecast
11.1. U.S
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Technology (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Product (2021-2033)
gChapter 12. Company Profiles
12.1. Roche Diagnostics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abbott Laboratories
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Thermo Fisher Scientific Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Illumina, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bio-Rad Laboratories, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Myriad Genetics, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Agilent Technologies, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Danaher Corporation (Cepheid)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hologic, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Foundation Medicine, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample